Daidzein
Names | |
---|---|
IUPAC name
7-Hydroxy-3-(4-hydroxyphenyl) chromen-4-one | |
Other names
4',7-Dihydroxyisoflavone Daidzeol Isoaurostatin | |
Identifiers | |
486-66-8 | |
ChEBI | CHEBI:28197 |
ChEMBL | ChEMBL8145 |
ChemSpider | 4445025 |
2828 | |
Jmol interactive 3D | Image |
KEGG | C10208 |
PubChem | 5281708 |
UNII | 6287WC5J2L |
| |
| |
Properties | |
C15H10O4 | |
Molar mass | 254.23 g/mol |
Appearance | Pale yellow prisms |
Melting point | 315 to 323 °C (599 to 613 °F; 588 to 596 K) (decomposes) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
Daidzein structurally belongs to the group of isoflavones.
Natural occurrences
Daidzein and other isoflavone compounds, such as genistein, are present in a number of plants and herbs like Kwao Krua (Pueraria mirifica) and Kudzu (Pueraria lobata). It can also be found in Maackia amurensis cell cultures.[2]
In food sources
Daidzein can be found in food such as soybeans and soy products like tofu and textured vegetable protein. Soy isoflavones are a group of compounds found in and isolated from the soybean. Of note, total isoflavones in soybeans are—in general—37 percent daidzein, 57 percent genistein and 6 percent glycitein, according to USDA data.[3] Soy germ contains 41.7 percent daidzein.[4]
Biological activities
Daidzein can be converted to its end metabolite S-equol in some humans based on the presence of certain intestinal bacteria. Based on several decades of research, S-equol has potential for significant health benefits.
Daidzein has no classification in the United States, where it is not considered to be generally recognized as safe (GRAS),[5] and has not been approved as a drug for any indication. It is a component of foods and dietary supplements derived from soy.[6] Dietary supplements are not regulated as drugs in the U.S., and the labeling of dietary supplements in the U.S. may not describe the supplement as having any drug activity or effectiveness.[7]
Scientists have studied some of the activities of daidzein in their laboratories, working with cells or with animals such as mice. Studies in cells and in animals sometimes give hints as to what a chemical might do when given to humans, but no one can know what a chemical does in humans until the chemical is tested in a clinical trial.
Daidzein has been found to act as an agonist of the GPER (GPR30).[8]
Activation of PPARs
Daidzein transactivates all three PPAR isoforms, α, δ, and γ and influences target cells.[9]
Cell proliferation studies
Daidzein has both estrogenic and anti-estrogenic effects. Experiments in cells and in animals showed that lower concentrations stimulate breast tumor growth in in vitro and in vivo, and ihibits the antitumor effect of the cancer drug tamoxifen, but higher concentrations (above 10 μM) have the contrary effect.[10] T47D:A18/PKC alpha tumor growth was demonstrated to be stimulated by genistein, but partially inhibited by daidzein; however, coadministration of tamoxifen with either daidzein or genistein produced tumors of greater size.[11]
Antioxidant
Scientific studies of daidzein's antioxidant properties have given contradictory results: some studies have shown antioxidant properties in laboratory experiments on cells, but in other experiments daidzein has caused oxidative stress on cells.[12]
Daidzein metabolite S-equol activities
Daidzein, when consumed from soy, is transformed in some humans, but not all, to produce S-equol [7-hydroxy-3-(49-hydroxyphenyl)-chroman],[13] Because it is a metabolite of daidzein, S-equol is not of plant origin. The molecular and physical structure of S-equol is similar to that of estradiol,[14] the main sex hormone found in women.
The ability to transform daidzein into S-equol is based on the presence of certain intestinal bacteria. In fact, several studies indicate that only 25 to 30 percent of the adult population of Western countries produces S-equol after eating soy foods containing isoflavones,[14][15][16][17] significantly lower than the reported 50 to 60 percent frequency of equol-producers in adults from Japan, Korea, or China.[18][19][20][21]
Although still under investigation, the ability to produce S-equol may be associated with other health benefits, according to data from epidemiological and clinical trials. Studies in both animal models and humans have yielded data about the potential of S-equol use in menopause[22][23] breast and prostate cancer,[14] and bone health.[24][25]
Glycosides
List of plants that contain the chemical
- Pueraria lobata[26][27]
- Pueraria thomsonii[28]
References
- ↑ Merck Index, 11th Edition, 2805.
- ↑ Isoflavonoid production by callus cultures of Maackia amurensis. S.A Fedoreyev, T.V Pokushalov, M.V Veselova, L.I Glebko, N.I Kulesh, T.I Muzarok, L.D Seletskaya, V.P Bulgakov and Yu.N Zhuravlev, Fitoterapia, 1 August 2000, Volume 71, Issue 4, Pages 365–372, doi:10.1016/S0367-326X(00)00129-5
- ↑ "Isoflavones contents of food". Top Cultures. Retrieved 2012-05-15.
- ↑ Zhang, Y.; Wang, G. J.; Song, T. T.; Murphy, P. A.; Hendrich, S. (1999). "Urinary disposition of the soybean isoflavones daidzein, genistein and glycitein differs among humans with moderate fecal isoflavone degradation activity". The Journal of Nutrition 129 (5): 957–962. PMID 10222386.
- ↑ FDA GRAS database
- ↑ Fact Sheet On The Phytoestrogen Daidzein
- ↑ FDA 101: Dietary Supplements
- ↑ Prossnitz, Eric R.; Barton, Matthias (2014). "Estrogen biology: New insights into GPER function and clinical opportunities". Molecular and Cellular Endocrinology 389 (1-2): 71–83. doi:10.1016/j.mce.2014.02.002. ISSN 0303-7207.
- ↑ Dang Z. C.; Löwik, C. (2004). "The Balance between Concurrent Activation of ERs and PPARs Determines Daidzein-Induced Osteogenesis and Adipogenesis". Journal of Bone and Mineral Research 19 (5): 853–861. doi:10.1359/jbmr.040120. PMID 15068509.
- ↑ de Lemos, M. L. (2001). "Effects of soy phytoestrogens genistein and daidzein on breast cancer growth.". Annals of Pharmacotherapy 35 (9): 11118–11121. doi:10.1345/aph.10257. PMID 11573864.
- ↑ Tonetti, D. A.; Zhang, Y.; Zhao, H.; Lim, S. B.; Constantinou, A. I. (2007). "The effect of the phytoestrogens genistein, daidzein, and equol on the growth of tamoxifen-resistant T47D / PKCα". Nutrition and Cancer 58 (2): 1222–1229. doi:10.1080/01635580701328545. PMID 17640169.
- ↑ Röhrdanz, E.; Ohler, S.; Tran-Thi, Q. H.; Kahl, R. (2002). "The Phytoestrogen Daidzein Affects the Antioxidant Enzyme System of Rat Hepatoma H4IIE Cells" (pdf). Journal of Nutrition 132 (2): 370–375. PMID 11880557.
- ↑ Setchell, K. D.; Clerici, C. (2010). "Equol: History, Chemistry, and Formation" (pdf). The Journal of Nutrition 140 (7): 1355S–1362S. doi:10.3945/jn.109.119776. PMC 2884333. PMID 20519412.
- 1 2 3 Atkinson, C.; Frankenfeld, C. L.; Lampe, J. W. (2005). "Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health" (pdf). Experimental Biology and Medicine 230 (3): 155–170. PMID 15734719.
- ↑ Lampe, J. W.; Karr, S. C.; Hutchins, A. M.; Slavin, J. L. (1998). "Urinary Equol Excretion with a Soy Challenge: Influence of Habitual Diet". Proceedings of the Society for Experimental Biology and Medicine 217 (3): 335–339. doi:10.3181/00379727-217-44241. PMID 9492344.
- ↑ Setchell, K. D.; Cole, S. J. (2006). "Method of Defining Equol-Producer Status and its Frequency among Vegetarians" (pdf). The Journal of Nutrition 136 (8): 2188–2193. PMID 16857839.
- ↑ Rowland, I. R.; Wiseman, H.; Sanders, T. A.; Adlercreutz, H.; Bowey, E. A. (2000). "Interindividual Variation in Metabolism of Soy Isoflavones and Lignans: Influence of Habitual Diet on Equol Production by the Gut Microflora". Nutrition and Cancer 36 (1): 27–32. doi:10.1207/S15327914NC3601_5. PMID 10798213.
- ↑ Watanabe, S.; Yamaguchi, M.; Sobue, T.; Takahashi, T.; Miura, T.; Arai, Y.; Mazur, W.; Wähälä, K.; Adlercreutz, H. (1998). "Pharmacokinetics of Soybean Isoflavones in Plasma, Urine and Feces of Men after Ingestion of 60 g Baked Soybean Powder (Kinako)" (pdf). The Journal of Nutrition 128 (10): 1710–1715. PMID 9772140.
- ↑ Arai, Y.; Uehara, M.; Sato, Y.; Kimira, M.; Eboshida, A.; Adlercreutz, H.; Watanabe, S. (2000). "Comparison of Isoflavones among Dietary Intake, Plasma Concentration and Urinary Excretion for Accurate Estimation of Phytoestrogen Intake" (pdf). Journal of Epidemiology 10 (2): 127–135. doi:10.2188/jea.10.127. PMID 10778038.
- ↑ Akaza, H.; Miyanaga, N.; Takashima, N.; Naito, S.; Hirao, Y.; Tsukamoto, T.; Fujioka, T.; Mori, M.; Kim, W. J.; Song, J. M.; Pantuck, A. J. (2004). "Comparisons of Percent Equol Producers between Prostate Cancer Patients and Controls: Case-controlled Studies of Isoflavones in Japanese, Korean and American Residents" (pdf). Japanese Journal of Clinical Oncology 34 (2): 86–89. doi:10.1093/jjco/hyh015. PMID 15067102.
- ↑ Song, K. B.; Atkinson, C.; Frankenfeld, C. L.; Jokela, T.; Wähälä, K.; Thomas, W. K.; Lampe, J. W. (2006). "Prevalence of Daidzein-Metabolizing Phenotypes Differs between Caucasian and Korean American Women and Girls" (pdf). The Journal of Nutrition 136 (5): 1347–1351. PMID 16614428.
- ↑ Aso, T.; Uchiyama, S.; Matsumura, Y.; Taguchi, M.; Nozaki, M.; Takamatsu, K.; Ishizuka, B.; Kubota, T.; Mizunuma, H.; Ohta, H. (2012). "A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women". Journal of Women's Health 21 (1): 92–100. doi:10.1089/jwh.2011.2753. PMID 21992596.
- ↑ Jou, H. J.; Wu, S. C.; Chang, F. W.; Ling, P. Y.; Chu, K. S.; Wu, W. H. (2008). "Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones". International Journal of Gynaecology and Obstetrics 102 (1): 44–49. doi:10.1016/j.ijgo.2008.01.028. PMID 18395723.
- ↑ Wu, J.; Oka, J.; Ezaki, J.; Ohtomo, T.; Ueno, T.; Uchiyama, S.; Toda, T.; Uehara, M.; Ishimi, Y. (2007). "Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial". Menopause 14 (5): 866–874. doi:10.1097/gme.0b013e3180305299. PMID 17464237.
- ↑ Tousen, Y.; Ezaki, J.; Fujii, Y.; Ueno, T.; Nishimuta, M.; Ishimi, Y. (2011). "Natural S-Equol Decreases Bone Resorption in Postmenopausal, Non-Equol-Producing Japanese Women: A Pilot Randomized, Placebo-Controlled Trial". Menopause 18 (5): 563–574. doi:10.1097/gme.0b013e3181f85aa7. PMID 21252728.
- ↑ Chen, G.; Zhang, J.; Ye, J. (2001). "Determination of Puerarin, Daidzein and Rutin in Pueraria lobata (Willd.) Ohwi by Capillary Electrophoresis with Electrochemical Detection". Journal of Chromatography A 923 (1–2): 255–262. doi:10.1016/S0021-9673(01)00996-7. PMID 11510548.
- ↑ Xu, H.-N.; He, C.-H. (2007). "Extraction of Isoflavones from Stem of Pueraria lobata (Willd.) Ohwi Using n-Butanol / Water Two-Phase Solvent System and Separation of Daidzein". Separation and Purification Technology 56 (1): 255–262. doi:10.1016/j.seppur.2007.01.027.
- ↑ Zhou, H. Y.; Wang, J. H.; Yan, F. Y. (2007). "[Separation and Determination of Puerarin, Daidzin and Daidzein in Stems and Leaves of Pueraria thomsonii by RP-HPLC]". Zhongguo Zhong Yao Za Zhi (in Chinese) 32 (10): 937–939. PMID 17655152.
|
|
|
|